Current Month 2010
Article Features
  Alcohol Intake Increases Certain Types of Breast Cancer
Boosting the Efficacy of Anticancer Vaccines
Continued Cancer Risk Found for Long-Term Hormone Therapy
Genes Identified That Could Be Associated with Aggressive Breast Cancer
Genetic Mutations Determine Breast Cancer Subtype
Genetic Risk Score Associated with Breast Cancer Risk, Predictive of Type of Disease
Guidelines for Whole Breast Irradiation Published
Male Breast Cancer in Family Leads to High Perception of Risk, Low Likelihood of Genetic Counseling
New Drug Reduces Tumor Size in Women with Advanced Hereditary Ovarian or Breast Cancer
New Imaging Technique Could Help Physicians Ease Lymphedema Symptoms
New Nuclear Breast Imaging Technologies Associated with Higher Cancer Risks
Nicotine Binding to Receptor Linked to Breast Cancer Cell Growth
Oral Contraceptive Use Associated with Increased Risk of Breast Cancer
Protein Made By Breast Cancer Gene Purified
Researchers Identify Role of Breast Cancer Oncogene
Special Yoga Classes Aimed at Breast Cancer Survivors Improve Recovery
Study Finds Air Travel Will Not Worsen Lymphedema in Breast Cancer Survivors
Study Finds Diet and Alcohol Alter Epigenetics of Breast Cancer and Could Prevent Severity of Disease
Women in Their 40s Have Lower Mammographic Tumor Detectability

Iron-Regulating Protein is Strong Predictor of Breast Cancer Prognosis

A new study by researchers at Wake Forest University Baptist Medical Center (WFUBMC) may soon help to spare some women with breast cancer from having to undergo invasive and toxic treatments for their disease.

Investigators found that low levels of ferroportin, the only known protein to eliminate iron from cells, are associated with the most aggressive and recurring cancers. The finding suggests that testing for ferroportin levels in women with breast cancer may one day help doctors to more accurately predict whether their patients' cancer will return. It may also help some women with high levels of the protein to avoid invasive or toxic treatments such as chemotherapy.

The study, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH), was published in the journal Science Translational Medicine.

"Ferroportin expression may help predict whether women who have had breast cancer will relapse or not," said Frank M. Torti, M.D., M.P.H., director of the Comprehensive Cancer Center at WFUBMC, senior author on the paper and co-lead investigator for the study. The findings also suggest that levels of ferroportin may eventually help guide therapy for breast cancer patients.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon